ALEC stock icon

Alector
ALEC

$4.93
4.89%
 

About: Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Employees: 244

0
Funds holding %
of 6,689 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

33,800% more call options, than puts

Call options by funds: $408K | Put options by funds: $1.2K

59% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 37

56% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 18

7% more funds holding

Funds holding: 145 [Q4 2023] → 155 (+10) [Q1 2024]

1.37% more ownership

Funds ownership: 75.96% [Q4 2023] → 77.32% (+1.37%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

13% less capital invested

Capital invested by funds: $510M [Q4 2023] → $446M (-$64.3M) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$15
204%
upside
Avg. target
$30
515%
upside
High target
$41
732%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
610%upside
$35
Buy
Maintained
9 May 2024
HC Wainwright & Co.
Andrew Fein
732%upside
$41
Buy
Reiterated
28 Feb 2024
Stifel
Paul Matteis
204%upside
$15
Buy
Upgraded
14 Dec 2023

Financial journalist opinion